Abstract: When prostate biopsy cores are separately identified in multiple containers, current recommendations are to grade each specimen individually. For treatment algorithms, the highest Gleason score (HGS) is typically used as the overall score, even if a lower score predominates. This practice has the potential to misrepresent the overall cancer in the entire gland for some patients and place them in a higher-grade group. We compare a novel composite Gleason score (CGS), integrating grade patterns from contiguous positive biopsy sites, with HGS to determine correlation with the radical prostatectomy (RP) Gleason score (GS). One hundred needle biopsy cases from 2008 to 2012 with >2 GSs in a biopsy set (eg, 3+3 = 6, 3+4 = 7, and 4+3 = 7) or more than a 1-step difference in GS (eg, 3+4 = 7 and 4+4 = 8 without 4+3 = 7) were analyzed. Grades were assigned using both methods (HGS and CGS) and compared with RPGS. Grade groups I to V were used to define downgrade and upgrade. Comparing HGS with RPGS, 31% remained the same and 69% had a change in GS (87% downgraded and 13% upgraded). Comparing CGS with RPGS, 59% remained the same and 41% had a change in GS (10% downgraded and 90% upgraded). Of the 2 methods, the CGS showed better overall correlation with RP (P < 0.001) and was less likely to be downgraded compared with HGS. CGS correlates better with RPGS than HGS when >2 grades are present in a biopsy set. CGS has a significantly lower rate of downgrade and predicts the RPGS more accurately than HGS.
T he Gleason grading system for prostatic adenocarcinoma is a unique and widely accepted grading system based on the architectural pattern. It is reproducible, predicts outcome, and has stood the test of time for many decades, with some recent modifications. When the Gleason score (GS) was first introduced in 1966, 1 screening for prostate cancer was primarily by digital rectal examination. After the introduction of prostatespecific antigen screening, multiple thin cores taken from different sites in the prostate gland became the primary specimen from which prostate cancer is diagnosed. Improvements in surgical techniques and consensus on pathologic reporting have led to improved assessment of radical prostatectomy (RP) specimens. For example, recognition of multiple tumor nodules and directed grading and staging of the dominant nodule(s) provides key prognostic information regarding tumor behavior. 2 These changes in practice and many issues not addressed in the original Gleason grading system led to modifications to the Gleason grading system, allowing better application by pathologists in current day practice. 1, 2 Despite improvements over time, the Gleason grading system correlation between prostate biopsy and RP remains variable, with concordance rates ranging from 41.3% to 63%, upgrade rates ranging from 21.9% to 47.4%, and downgrade rates ranging from 5% to 20.7%. [3] [4] [5] [6] [7] [8] [9] [10] Despite multiple studies assessing concordance in GS between biopsy and prostatectomy, only a minority have focused on implications and possible causes of discordance. A few studies reported a higher rate of downgrade when assessing heterogenous tumors, ranging from 27.2% to 47%, [11] [12] [13] and others have reported a 2 or more GS discrepancy level ranging from 8.6% to 26%. 14, 15 Such discrepancies between the prostate biopsy GS and the overall tumor characteristics in the entire prostate gland might result in inappropriate treatment recommendations. Therefore, accurate Gleason scoring is critical for patient management.
As per the current International Society of Urological Pathology (ISUP) guidelines, individual cores should be graded separately. The core with the highest Gleason score (HGS) typically is used as a parameter in treatment algorithms, combined with the prostate-specific antigen level, clinical stage, and other factors. In addition, the 2005 ISUP Consensus on Gleason grading recommends different algorithms of assigning GS in needle biopsy and RP specimens when 3 different Gleason grade patterns are present in a tumor. 2 Hence, there will be inherent differences between the scores generated by these 2 methods, even for the same tumor. If an accurate representation of the tumor in the entire prostate gland is desired, reporting the predominant and highest Gleason grade patterns, as recommended for needle biopsy, will sometimes overestimate the RPGS. Conversely, other data suggest that even a minor component of higher-grade tumor at needle biopsy is important and has significant implications for outcome, even if not reflective of the overall tumor grade. [16] [17] [18] [19] In this study, we propose a method of assigning a composite Gleason score (CGS) on the basis of a constellation of needle biopsy findings, and compare this method with traditional HGS in predicting RPGS, specifically when >2 GSs are seen in a biopsy set.
MATERIALS AND METHODS
This study was reviewed and approved by the Henry Ford Health System Institutional Review Board. We analyzed 1193 patients between January 2009 and August 2012 with prostate needle biopsy sets, of which 197 had >2 GSs in 1 biopsy set (eg, 3+3 = 6, 3+4 = 7, and 4+3 = 7) or had >1-step difference in GS between separate biopsy cores (eg, 3+4 = 7 and 4+4 = 8 with no 4+3 = 7). Only cases with 10 or more biopsies were included, resulting in exclusion of 12 cases. Follow-up RP for treatment of prostatic adenocarcinoma was available in 100 patients. Each biopsy set was examined, and 2 methods of assigning an overall GS were compared: (1) the HGS, and (2) a CGS. The CGS attempted to predict the overall tumor characteristics by assigning a final GS to the entire biopsy set on the basis of positive cores from contiguous anatomic locations of the presumed dominant nodule. The tumor morphology in these separate cores was required to be similar to be included in the composite grading. Other positive biopsy sites that were anatomically separate and morphologically different were hypothesized to arise from secondary nodules and were excluded from the composite score. The rationale of excluding separate secondary nodules is that they could potentially dilute the higher tumor grade of the dominant tumor, which drives clinical decision-making (Fig. 1) .
We recorded percentages and lengths of cancer involvement and relative proportions of each Gleason grade pattern on each positive needle core. Total percentage of each Gleason pattern was estimated on the entire set of contiguous positive cores that were morphologically similar. Variables studied included age, number of cores, number and location of positive cores, prostate needle biopsy GS and RPGS, CGS, grade group, 20 tumor volume and percentage of involvement for each Gleason pattern, pathologic stage, surgical margin status, and lymph node status. All RP specimens were processed using the whole-mount technique, and the entire prostate tissue was examined microscopically. The prostate needle biopsies and RP were graded according to the modified Gleason grading system using the guidelines established by the 2005 ISUP consensus. 2 Categories of GS were also divided according to grade groups I to V proposed by Pierorazio et al, 20 to define correlation and upgrade or downgrade in GS when compared with RP. The CGSs and the HGSs were compared with RPGSs using the Bowker test of symmetry. The Spearman correlation coefficient was used to correlate each method with RPGS, stage, and positive margin.
RESULTS
The pathologic characteristics of the overall study population and RP characteristics are shown in Tables 1  and 2 .
Relation Between Highest Needle Biopsy GS and RPGS
Of the 100 cases, only 31% cases showed the same RPGS as the highest needle biopsy GS. Sixty-nine cases (69%) had a different RPGS compared with the highest needle biopsy GS. Of the cases that had a change in GS, 87% (60/69) were downgraded at RP, and 13% (9/69) were upgraded ( Fig. 2A) . From the cases that were downgraded, 2% (1/60) had a 3-level downgrade in grade group, 20% (12/60) had a 2-level downgrade, and 78% (47/60) had a 1-level downgrade (Fig. 2B ).
Relation Between Composite Needle Biopsy GS and RPGS
In 59% of cases the RPGS was the same as the composite needle biopsy GS. Only 41% had a different RPGS compared with the composite needle biopsy GS. Of the cases that had a change in GS, 10% (4/41) were downgraded at RP and 90% (37/41) were upgraded (Fig. 3A) . From the cases that were downgraded, none had a 3-level downgrade grade group variation, 25% (1/4) had a 2-level downgrade, and 75% (3/4) had a 1-level downgrade. Of the upgraded cases, 65% (24/37) had a 1-level grade group upgrade, 30% (11/37) had a 2-level upgrade, and 5% (2/37) had a 3-level upgrade (Fig. 3B) .
The relationships between the HGS, CGS, and the final RPGS are shown in Tables 3-5 . When comparing the correlation of the 2 methods with the final RPGS, both methods showed significant correlation with RPGS. The CGS method was less likely to be downgraded and more likely to be upgraded than the HGS and showed a better correlation overall (P < 0.001) ( Table 3) .
DISCUSSION
In this study, we sought to assess whether a CGS, combining the findings from all positive needle biopsies from a presumed dominant cancer nodule (Fig. 1) , would more accurately predict the overall cancer status in the entire gland than the traditionally used highest single needle biopsy score. We found that when a prostate biopsy set contains >2 GSs (eg, 3+3 = 6, 3+4 = 7, and 4+3 = 7), or a 2-step difference in GS (eg, 3+4 = 7 and 4+4 = 8), using the HGS from all biopsy sites as the overall score overestimates the RPGS with a significantly higher downgrade rate (60%) compared with a CGS (4%). The agreement between the GS of the prostate needle biopsy sets and RP specimens improved significantly (P = 0.001) from 31% when using the HGS to 59% when using a CGS.
Before the 2005 ISUP consensus, the rate of concordance between prostate needle biopsy GS and RPGS ranged from 29.2% to 68%. Of discordant cases, GS upgrading appeared to be more common than downgrading, with an upgrade rate ranging from 25% to 55.7% and a downgrade rate ranging from 6% to 36%. 6, 10, [13] [14] [15] [21] [22] [23] [24] [25] After the 2005 ISUP modifications, many studies have shown improvements of concordance between biopsy GS and RPGS, stage, low-grade and highgrade cancers, and biochemical recurrence. Also, there has been a shift toward higher tumor grades and a decrease in upgrading. 6, 10, 20, [26] [27] [28] [29] However, despite these improvements, the Gleason grading system still has limitations, and correlation between prostate biopsy and RPGSs remains imperfect. The reported concordance rate after the 2005 ISUP consensus ranges from 41.3% to 63%. Of discordant cases, upgrading ranges from 21.9% to 47.4% and downgrading ranges from 5% to 20.7%. [3] [4] [5] [6] [7] [8] [9] [10] Our results, when using the HGS, show an exact concordance of only 31%, upgrade of 9%, and downgrade of 60%. Our values are very different compared with other studies, as we have a highly selective group of patients with >2 GSs on needle biopsy set, whereas other studies report general concordance data. This comparison demonstrates that, although ISUP recommendations on reporting prostate cancer on needle biopsy works very well in some scenarios, it fails to provide an accurate assessment of the final prostatectomy GS when >2 GSs are present in the same biopsy set. This is perhaps not unexpected, as the 2005 ISUP consensus recommends that a minor higher-grade pattern be included in the GS in the needle biopsy setting, but not necessarily in the RP setting. 2 The discrepancy in GS between prostate needle biopsy and RP may result in inappropriate treatment recommendations. In this study, although there is a higher rate of upgrading when using the CGS, the overall rate of correlation with the final grade significantly improves with composite grading compared with HGS (59% vs. 31%). High level of correlation with the final GS of the tumor at the initial diagnosis is very important as it can impact the management of the patient. Low-risk patients often receive monotherapy (RP, external beam radiation, interstitial brachytherapy), and intermediate-risk and highrisk patients would receive combined therapy (external beam radiation plus hormonal therapy or external beam radiation plus brachytherapy with or without hormonal (20) 1 (5) 1 (5) 4 (20) 1 (5) (14) 62 (41-77) 1 (7) 1 (7) 8 (57) 4 (29) 8 (57) (30) 40 (40) 27 (24) 1 (1) 27 (27) 17 (17) 3 . A, Using the proposed CGS method, the RPGS was predicted accurately in the majority of patients, although upgrading was more common when compared with HGS. B, Most patients had the same grade group when comparing CGS with RPGS. A smaller number of patients were upgraded to a higher-grade group category, usually by 1 step.
therapy or RP with postoperative therapy, depending upon final pathology). The grade of differentiation established by using the Gleason scoring system is 1 of many variables used in nomograms to guide treatment options, and as per our study the HGS system tends to overgrade a high percentage of cases, hence influencing the decision-making process for the patient and the clinicians. The impact of misclassification gains even more relevance after the 2005 ISUP consensus, as there is a tendency toward higher tumor grades. 30 Despite multiple studies assessing GS concordance, few studies have focused on downgrading, its implications, and possible causes. [11] [12] [13] Special consideration is needed in the pattern of variability of GSs in a prostate needle biopsy set as a possible cause of misclassification. Borderline grades have been suggested as a reason for upgrade, 31 and it remains incompletely understood whether a 50% threshold for identifying more aggressive tumor biology (eg,. 3+4 = 7 vs. 4+3 = 7, and so on) is optimal. Similar to our current study, Reese and colleagues proposed a simple modification of the current Gleason grading system based on the weighted average of Gleason patterns. The authors specifically studied GS 7 cancers and found that this method improved the correlation between biopsy GS and RPGS, as well as the prediction of biochemical disease recurrence after RP. 32 One of the ISUP 2005 consensus recommendations was to assign individual GSs to separate cores when the cores are submitted in separate containers. 2 It is not uncommon to encounter a small higher-grade tumor focus in 1 needle biopsy, contrasting to other cores from the same biopsy set that contain larger areas of lower-grade cancer. In this scenario, it would seem intuitively likely that the higher-grade component makes up only a small fraction of the overall tumor, particularly if the positive biopsies are taken from adjacent anatomic sites. For treatment purposes, most clinicians use the HGS from the biopsy set, regardless of the overall volume of this highergrade component, to determine treatment. 33 This approach may be the cause of a large proportion of downgrading in patients with heterogenous tumors. Few studies have evaluated prostate needle biopsy sets with different GSs showing a higher tendency of downgrade. When assessing cases with tumor heterogeneity, rates of downgrade have ranged from 27.2% to 47%, which is significantly higher than reported overall rates of downgrade. [11] [12] [13] These findings are comparable to our results, showing a higher rate of downgrading when evaluating patients with >than 2 GSs or a 2-step difference in GS. When using the highest biopsy GS, we found that 60% of such patients had a downgraded GS at RP. The higher downgrade compared with that found by Park et al 12 and Poulos et al 13 may be explained due to the use of 3 categories only. Differences as compared with the findings of Gonzalgo et al 11 may be due to the evaluation of patients with GS 7 only.
The importance of our findings is not only the high rate of downgrade in these particular cases but the level of downgrade of >1 GS. Cookson et al 14 and Fukagai et al 15 found that 26% and 8.6% of cases, respectively, were discrepant by 2 or more GSs. In our data, of the 60% of cases downgraded, 78% were downgraded by 1 grade group, 20% were downgraded by 2 grade groups, and 2% were downgraded by 3 grade groups, supporting the idea that in some patients the highest needle biopsy GS significantly overestimates the higher-grade tumor burden in the gland as a whole. Further studies applying a CGS in larger patient populations, including correlation with outcomes, and application to additional grading scenarios will be useful to validate our results and the utility of CGS overall. Even if HGS remains the standard for use in prognostic nomograms and algorithms, applying a CGS may be helpful as an additional ancillary tool in guiding decision-making and in counseling patients regarding biopsy and prostatectomy discrepancies in GS. The role of the CGS in patients presenting with only a 1-step difference in GS remains to be studied.
In conclusion, a composite needle biopsy GS combining relative proportions of each Gleason grade pattern in multiple contiguous positive biopsies correlates better with RPGS in patients with heterogenous needle biopsy GSs (> 2 different GSs or a 2-step difference in GS between separate biopsies). The CGS has a significantly lower rate of downgrade and predicts the RPGS more II  III  IV  V   RP grade group  II  23  3  1  -III  19  30  --IV  2  5  1  -V  2  9  -5 Green boxes indicate exact concordance.
accurately than HGS (P < 0.001). Although the CGS has a greater likelihood of upgrade at RP compared with the HGS, this rate is comparable to current averages. Tumor heterogeneity represented by >2 different GSs or a 2-step difference in GS frequently results in a higher and significant rate of downgrade when the HGS is used as the overall biopsy score. These cases may represent the majority of downgraded patients seen in studies that include all GSs, of which some have a >2 grade group downgrade. A CGS may be offered as an ancillary diagnostic tool when encountering a patient with a prostate needle biopsy set showing >2 GSs or a 2-step difference in GS, as the highest needle biopsy GS correlates poorly with the final RPGS in this scenario.
